EUVIMEDEUVIMED entdecken
Open Access

Phage-antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa in in vitro static and dynamic biofilm models

Dana J Holger iD, Amer El Ghali, Natasha Bhutani, Katherine L Lev, Kyle Stamper, Razieh Kebriaei, Ashlan J Kunz Coyne, Taylor Morrisette, Rahi Shah, Jose Alexander, Susan M Lehman, Laura J Rojas und 3 weitere

Antimicrobial Agents and Chemotherapy · 2023

DOI: 10.1128/aac.00578-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2023. Verfasst von Dana J Holger und 14 weiteren Autor:innen. Beteiligte Einrichtung: Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University…. Hauptthemen laut MEDLINE: Bacteriophages, Pseudomonas Infections. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biofilm-producing Pseudomonas aeruginosa infections pose a severe threat to public health and are responsible for high morbidity and mortality. Phage-antibiotic combinations (PACs) are a promising strategy for combatting multidrug-resistant (MDR), extensively drug-resistant (XDR), and difficult-to-treat P. aeruginosa infections. Ten MDR/XDR P. aeruginosa strains and five P . aeruginosa -specific phages were genetically characterized and evaluated based upon their antibiotic susceptibilities and phage sensitivities. Two selected strains, AR351 (XDR) and I0003-1 (MDR), were treated singly and in combination with either a broad-spectrum or narrow-spectrum phage, phage EM-T3762627-2_AH (EM), or 14207, respectively, and bactericidal antibiotics of five classes in biofilm time-kill analyses. Synergy and/or bactericidal activity was demonstrated with all PACs against one or both drug-resistant P. aeruginosa strains (average reduction: −Δ3.32 log 10 CFU/cm 2 ). Slightly improved ciprofloxacin susceptibility was observed in both strains after exposure to phages (EM and 14207) in combination with ciprofloxacin and colistin. Based on phage cocktail optimization with four phages (EM, 14207, E20050-C (EC), and 109), we identified several effective phage-antibiotic cocktails for further analysis in a 4-day pharmacokinetic/pharmacodynamic in vitro biofilm model. Three-phage cocktail, EM + EC + 109, in combination with ciprofloxacin demonstrated the greatest biofilm reduction against AR351 (−Δ4.70 log 10 CFU/cm 2 from baseline). Of remarkable interest, the addition of phage 109 prevented phage resistance development to EM and EC in the biofilm model. PACs can demonstrate synergy and offer enhanced eradication of biofilm against drug-resistant P. aeruginosa while preventing the emergence of resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BacteriophagesPseudomonas InfectionsHumansPseudomonas aeruginosaAnti-Bacterial AgentsCiprofloxacinBiofilms

Stichwörter der Autor:innen

MDRPseudomonas aeruginosaantibioticsantimicrobial combinationsantimicrobial resistancebacteriophagebiofilmscocktailphagesynergy

Substanzen

Anti-Bacterial AgentsCiprofloxacin

Autor:innen und Institutionen

  • Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University , Detroit, Michigan, USA.
  • Department of Microbiology, Virology, and Immunology, AdventHealth Central Florida , Orlando, Florida, USA.
  • Center for Biologics Evaluation and Research, U.S. Food and Drug Administration , Silver Spring, Maryland, USA.
  • Department of Molecular Biology and Microbiology, School of Medicine, Case Western Reserve University , Cleveland, Ohio, USA.
  • Center for Antimicrobial Resistance and Epidemiology, Veterans Affairs Medical Center, Case Western Reserve University , Cleveland, Ohio, USA.
  • Research Service, Louis Stokes Veterans Affairs Medical Center , Cleveland, Ohio, USA.

ORCID-Profile: Dana J Holger, Michael J Rybak

Förderung

  • NIAID NIH HHS

Zitieren

APA

Holger, D. J., El Ghali, A., Bhutani, N., Lev, K. L., Stamper, K., Kebriaei, R., Kunz Coyne, A. J., Morrisette, T., Shah, R., Alexander, J., Lehman, S. M., Rojas, L. J., Marshall, S. H., Bonomo, R. A., & Rybak, M. J. (2023). Phage-antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa in in vitro static and dynamic biofilm models. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00578-23

Vancouver

Holger DJ, El Ghali A, Bhutani N, Lev KL, Stamper K, Kebriaei R, et al. Phage-antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa in in vitro static and dynamic biofilm models. Antimicrobial Agents and Chemotherapy. 2023. doi:10.1128/aac.00578-23

BibTeX
@article{Holger2023,
  author = {Holger, Dana J and El Ghali, Amer and Bhutani, Natasha and Lev, Katherine L and Stamper, Kyle and Kebriaei, Razieh and Kunz Coyne, Ashlan J and Morrisette, Taylor and Shah, Rahi and Alexander, Jose and Lehman, Susan M and Rojas, Laura J and Marshall, Steven H and Bonomo, Robert A and Rybak, Michael J},
  title = {Phage-antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa in in vitro static and dynamic biofilm models},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  doi = {10.1128/aac.00578-23}
}
Kostenlos starten →